30-day roundup
The 10 most notable cure or vaccine studies from the last month.
A trial tests different conditioning regimens before stem cell transplants in children with acute lymphoblastic leukemia to improve survival.
Read lead report →A trial tests CTX112, an engineered T-cell therapy, for severe neurologic autoimmune diseases like progressive MS and stiff-person syndrome.
Read report →An early trial tests a gene therapy for homozygous familial hypercholesterolemia, aiming to lower LDL cholesterol by restoring LDL receptor function.
Read report →A gene therapy trial tests whether modified stem cells can treat metachromatic leukodystrophy, a rare genetic disease.
Read report →A phase 1 trial tests combining focused ultrasound with T-cell therapy for diffuse midline glioma, a rare brain tumor.
Read report →A Phase 1 trial tests whether a single infusion of allogeneic CAR-T cells can reset the immune system in people with severe autoimmune diseases.
Read report →A trial tests gene-modified stem cells to correct the faulty gene behind beta thalassemia, aiming for a lasting fix without lifelong transfusions.
Read report →A trial tests whether base-edited stem cells can cure WHIM syndrome, a rare immune disorder causing severe infections.
Read report →A trial testing YOLT-204, a gene therapy for sickle cell disease and transfusion-dependent thalassemia, aims to boost fetal hemoglobin and reduce transfusions.
Read report →A Phase III trial tests whether a dual-targeting CAR-T therapy (AZD0120) can outperform standard care in newly diagnosed multiple myeloma patients ineligible fo
Read report →Trials whose completion date fell in this window and whose status is actually Completed. Results usually follow later.